🇺🇸 FDA
Pipeline program

Chemoembolization and Response-Dependent Resection

HCC_S012

Approved other active

Quick answer

Chemoembolization and Response-Dependent Resection for Resectable Hepatocellular Carcinoma Beyond Milan Criteria is a Approved program (other) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Resectable Hepatocellular Carcinoma Beyond Milan Criteria
Phase
Approved
Modality
other
Status
active

Clinical trials